Literature DB >> 4020541

Acute splenic sequestration in homozygous sickle cell disease: natural history and management.

A M Emond, R Collis, D Darvill, D R Higgs, G H Maude, G R Serjeant.   

Abstract

Of a cohort of 308 children with homozygous sickle cell disease diagnosed at birth, 89 experienced 132 clinically significant attacks of acute splenic sequestration (ASS) over a 10-year period. The age at first attack ranged from 3 months to 6 years. Survival curve analysis of the interval until first attack indicated a cumulative probability of 0.225 by 2 years, and 0.265 by 3 years, and 0.297 by 5 years of age. Thirteen events were fatal, 11 during the first attack, and all before transfusion could be instituted. Recurrences occurred in 49% of survivors of the first attacks, and there were diminishing intervals between subsequent events. Respiratory symptoms were associated with 52 of 132 events, but bacterial isolates on blood culture were less frequent, and ASS was not prevented by pneumococcal vaccine or penicillin prophylaxis. A high fetal hemoglobin level protected against attacks of ASS. A parental education program aimed at early diagnosis of ASS was followed by an increase in the incidence rate for ASS from a mean of 4.6 per 100 patient-years to 11.3 per 100 patient-years, probably reflecting increased awareness of the complication. During the same periods, the fatality rate fell from 29.4 per 100 events to 3.1 per 100 events. The improvement in outcome is likely to have resulted from improvement in medical management and earlier detection of ASS.

Entities:  

Mesh:

Year:  1985        PMID: 4020541     DOI: 10.1016/s0022-3476(85)80125-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  46 in total

1.  Costing model for neonatal screening and diagnosis of haemoglobinopathies.

Authors:  E K Cronin; C Normand; J S Henthorn; M Hickman; S C Davies
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

2.  Fetal haemoglobin and early manifestations of homozygous sickle cell disease.

Authors:  K Bailey; J S Morris; P Thomas; G R Serjeant
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

3.  Mortality from sickle cell disease in Africa.

Authors:  Graham R Serjeant
Journal:  BMJ       Date:  2005-02-26

4.  Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany.

Authors:  Stephan Lobitz; Claudia Frömmel; Annemarie Brose; Jeannette Klein; Oliver Blankenstein
Journal:  Eur J Hum Genet       Date:  2014-01-08       Impact factor: 4.246

Review 5.  The natural history of sickle cell disease.

Authors:  Graham R Serjeant
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

6.  Newborn screening for sickle cell disease in India: the need for defining optimal clinical care.

Authors:  Jyotish Patel; Graham R Serjeant
Journal:  Indian J Pediatr       Date:  2013-09-14       Impact factor: 1.967

7.  Splenectomy and acute splenic sequestration crises in sickle cell disease.

Authors:  A H Al Salem; S Qaisaruddin; Z Nasserullah; I Al Dabbous; H Abu Srair; A Al Jam'a
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

8.  National trends in the mortality of children with sickle cell disease, 1968 through 1992.

Authors:  H Davis; K C Schoendorf; P J Gergen; R M Moore
Journal:  Am J Public Health       Date:  1997-08       Impact factor: 9.308

9.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

10.  Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified?

Authors:  M E Kizito; E Mworozi; C Ndugwa; G R Serjeant
Journal:  Arch Dis Child       Date:  2006-03-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.